in-stent restenosis

in-stent restenosis

Interventional cardiology Scar-induced reclosure of a previously stenosed coronary artery, a complication seen in ±20% of Pts undergoing stent placement for CAD. See Coronary artery disease, Stent. Cf Late stent thrombosis.
References in periodicals archive ?
Background: Currently, drug-eluting balloon (DEB) appears to be an attractive alternative option for the treatment of in-stent restenosis (ISR).
Following a heart-healthy diet, taking medications as prescribed, not smoking, and regular visits with your cardiologist are the best ways to reduce the likelihood of in-stent restenosis.
The product is indicated for a variety of uses, including: balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion; balloon dilatation of a coronary artery occlusion for the treatment of acute myocardial infarction; and dilatation of in-stent restenosis and post-delivery expansion of balloon expandable coronary stents.
Both products are indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion, balloon dilatation of a coronary artery occlusion for the treatment of acute myocardial infarction as well as for dilatation of in-stent restenosis and post-delivery expansion of balloon expandable coronary stents.
1 percent in the PTA group (p= 5 cm) (n=126) and in-stent restenosis (ISR) lesions (n=131), as recently presented at international conferences.
However, in-stent restenosis was seen five times more often with paclitaxel-eluting stents than with sirolimus-eluting stents.
M2 PHARMA-February 25, 2015-CBSET Defines Optimal Tissue Debulking Protocol Defined for Treating In-Stent Restenosis with Boston Scientific Device
A long-term follow-up study reports on the safety and success of drug-eluting balloon angioplasty in treating patients with carotid in-stent restenosis that has proven refractory to treatment with balloon angioplasty and/or redo stenting.
6, 22 males) undergoing successful CBA for the treatment of in-stent restenosis at our hospital were prospectively included in this study.
Six short communications consider such matters as the effect of insulin resistance on coronary in-stent restenosis, expressing inflammatory molecules in an experimental vascular remodeling model, and methods for assessing insulin resistance.
The company has also announced FDA approval of its TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System for the treatment of in-stent restenosis in bare-metal stents.
For bare-metal stents, the overall one-year rate of narrowing or in-stent restenosis requiring re-intervention is about 10-15%.

Full browser ?